E-ISSN 2231-3206 | ISSN 2320-4672
 

Original Research 


Fluoroquinolones in India—Are we prescribing it right: A cost variation study

Vihang S Chawan, Kalpesh V Gawand, Sagar V Badwane.

Cited by (1)

Abstract
Background: Quinolones are the fastest growing antibacterial agents worldwide as they are being used in both the hospitals and community practices to treat infections. Ciprofloxacin and levofloxacin dominate the market mostly, which together charge 65% ($3.3 billion) of global sales. Quinolones such as ciprofloxacin, levofloxacin, and moxifloxacin have been found to possess enormous market capacity and sales volume. Fluoroquinolones in India comprise 30% share of Global Pharmaceuticals Market counterparts.

Aims and Objective: To find out the cost of various oral fluoroquinolones available in India either as a single drug or in combination and to evaluate the difference in cost of various brands of same fluoroquinolone by calculating percentage variation in cost in Indian rupees.

Material and Methods: Cost of oral fluoroquinolones manufactured by different companies, in the same strength and dosage forms, was obtained from Current Index of Medical Specialties, July–October 2014, and Indian Drug Review, Vol. XXI, Issue No. 4, 2014. The difference in the maximum and minimum price of the same drug manufactured by different pharmaceutical companies and percentage variation in price was calculated.

Result: Percentage price variation for various fluoroquinolones was as follows: ofloxacin (200 mg) 869%; sparfloxacin (200 mg) 648%; gemifloxacin (320 mg) 477%; norfloxacin (400 mg) 291%; ciprofloxacin (500 mg) 290%; levofloxacin (250 mg) 264%; lomefloxacin (400 mg) 104%; and moxifloxacin (400 mg) 60%. Among the combination therapy, price variation was norfloxacin + tinidazole (400 + 600 mg) 983%; ofloxacin + cefixime (200 + 200 mg) 232%; levofloxacin + ornidazole (250 + 500 mg) 211%; ofloxacin + ornidazole (200 + 500 mg) 156.60%; and ciprofloxacin + tinidazole (500 + 600 mg) 150%.

Conclusion: The average percentage price variation of different brands of same oral fluoroquinolones manufactured in India is very wide. As India is a developing country, clinicians must prescribe fluoroquinolones keeping in mind the cost of therapy.

Key words: Fluoroquinolones; Cost Analysis; Price; Cost Variation


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Vihang S Chawan
Articles by Kalpesh V Gawand
Articles by Sagar V Badwane
on Google
on Google Scholar


REFERENCES
1. Kharab R, Sharma PC, Yar MS. Pharmacological significance of triazole scaffold J. Enzyme Inhib Med Chem. 2010;26:1-21. [DOI via Crossref]    [Pubmed]   
2. Chawla R, Sahoo U, Arora A, Sharma PC, Vijayaraj R. Microwave assisted synthesis of some novel 2-pyrazoline derivatives as possible antimicrobial agents. Acta Pol Pharm Drug Res. 2010;67(1):55-61.
3. Choudhury D, Talukdar AD, Maurya AP, Choudhury MD, Dhar Chanda D, Chakravarty A, et al. Contribution of efflux pumps in fluroquinolone resistance in multi-drug resistant nosocomial isolates of Pseudomanas aeruginosa from a tertiary referral hospital in north east India. Indian J Med Microbiol. 2015;33(1):84-6. [DOI via Crossref]    [Pubmed]   
4. Wu JJ, Ko WC, Tsai SH, Yan JJ. Prevalence of plasmid-mediated uinolone resistance determinants QnrA, QnrB, and QnrS among clinical isolates of Enterobacter cloacae in a Taiwanese hospital. Antimicrob Agents Chemother. 2007;51:1223-7. [DOI via Crossref]    [Pubmed]    [PMC Free Fulltext]   
5. Sharma PC, Jain A, Jain S, Pahwa R, Yar MS. Ciprofloxacin: review on developments in synthetic, analytical, and medicinal aspects. J Enzyme Inhib Med Chem. 2010;25(4):577-89. [DOI via Crossref]    [Pubmed]   
6. Sharma PC, Saneja A, Jain S. Norfloxacin: a therapeutic review. Int J Chem Sci. 2008;6(4):1702-13.
7. Sharma PC, Jain A, Jain S. Therapeutic perspectives of fluoroquinolone antibacterials: an update. Proceedings of the 1st Rashtriya Yuva Vaigyanik Sammelan. Kurukshetra: NIT, November 28-30, 2008. pp. 234-9.
8. Liu HH. Safety profile of the fluoroquinolones: focus on levofloxacin. Drug Saf. 2010;33(5):353-69. [DOI via Crossref]    [Pubmed]   
9. Sousa J, Alves G, Fortuna A, Falcão A. Third and fourth generation fluoroquinolone antibacterials: a systematic review of safety and toxicity profiles. Curr Drug Saf. 2014;9(2):89-105. [DOI via Crossref]    [Pubmed]   
10. Rifenburg RP, Paladino JA, Bhavnani SM, Haese DD, Schentag JJ. Influence of fluoroquinolone purchasing patterns on antimicrobial expenditures and Pseudomonas aeruginosa susceptibility. Am J Health Syst Pharm. 1999;56(21):2217-23. [Pubmed]   
11. Hooper D. Quinolones. In: Mandell GL, Bennett JE, Mandell DR (Eds.), Douglas and Bennett’s Principles and Practice of Infectious Disease, 5th ed. Philadelphia, PA: Churchill Livingstone, 2000. pp. 404-23.
12. In Recent Years, Bulk Drugs and Intermediates Ciprofloxacin Market Analysis. Available at: http://www.articlesbase.com/non-profitorganizations-articles/in-recent-years-bulk-drugs-and-intermediatesciprofloxacin-market-analysis-3498636.html [accessed April 15, 2015].
13. Frazier LM, Brown JT, Divine GW, Fleming GR, Philips NM, Siegal WC, et al. Can physician education lower the cost of prescription drugs? A prospective, controlled trial. Ann Intern Med. 1991;115(2):116-21. [DOI via Crossref]    [Pubmed]   
14. Badia X, Russo P, Attanasio E. A comparative economic analysis of simvastatin versus atorvastatin: results of the Surrogate Marker Cost-Efficacy (SMaC) study. Clin Ther. 1999;21(10):1788-96. Erratum in: Clin Ther. 1999;21(12):2186. [DOI via Crossref]   

This Article Cited By the following articles

Fluoroquinolones: Blessings Or Curses
CDT 2020; 21(13): 1354.

1
 
How to Cite this Article
Pubmed Style

Vihang S Chawan, Kalpesh V Gawand, Sagar V Badwane. Fluoroquinolones in India—Are we prescribing it right: A cost variation study. Natl J Physiol Pharm Pharmacol. 2015; 5(4): 306-308. doi:10.5455/njppp.2015.5.1604201547


Web Style

Vihang S Chawan, Kalpesh V Gawand, Sagar V Badwane. Fluoroquinolones in India—Are we prescribing it right: A cost variation study. https://www.njppp.com/?mno=185192 [Access: December 01, 2022]. doi:10.5455/njppp.2015.5.1604201547


AMA (American Medical Association) Style

Vihang S Chawan, Kalpesh V Gawand, Sagar V Badwane. Fluoroquinolones in India—Are we prescribing it right: A cost variation study. Natl J Physiol Pharm Pharmacol. 2015; 5(4): 306-308. doi:10.5455/njppp.2015.5.1604201547



Vancouver/ICMJE Style

Vihang S Chawan, Kalpesh V Gawand, Sagar V Badwane. Fluoroquinolones in India—Are we prescribing it right: A cost variation study. Natl J Physiol Pharm Pharmacol. (2015), [cited December 01, 2022]; 5(4): 306-308. doi:10.5455/njppp.2015.5.1604201547



Harvard Style

Vihang S Chawan, Kalpesh V Gawand, Sagar V Badwane (2015) Fluoroquinolones in India—Are we prescribing it right: A cost variation study. Natl J Physiol Pharm Pharmacol, 5 (4), 306-308. doi:10.5455/njppp.2015.5.1604201547



Turabian Style

Vihang S Chawan, Kalpesh V Gawand, Sagar V Badwane. 2015. Fluoroquinolones in India—Are we prescribing it right: A cost variation study. National Journal of Physiology, Pharmacy and Pharmacology, 5 (4), 306-308. doi:10.5455/njppp.2015.5.1604201547



Chicago Style

Vihang S Chawan, Kalpesh V Gawand, Sagar V Badwane. "Fluoroquinolones in India—Are we prescribing it right: A cost variation study." National Journal of Physiology, Pharmacy and Pharmacology 5 (2015), 306-308. doi:10.5455/njppp.2015.5.1604201547



MLA (The Modern Language Association) Style

Vihang S Chawan, Kalpesh V Gawand, Sagar V Badwane. "Fluoroquinolones in India—Are we prescribing it right: A cost variation study." National Journal of Physiology, Pharmacy and Pharmacology 5.4 (2015), 306-308. Print. doi:10.5455/njppp.2015.5.1604201547



APA (American Psychological Association) Style

Vihang S Chawan, Kalpesh V Gawand, Sagar V Badwane (2015) Fluoroquinolones in India—Are we prescribing it right: A cost variation study. National Journal of Physiology, Pharmacy and Pharmacology, 5 (4), 306-308. doi:10.5455/njppp.2015.5.1604201547